CERVARIX human papillomavirus vaccine types 16 and 18 [recombinant, AS04 adjuvanted] suspension for injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

cervarix human papillomavirus vaccine types 16 and 18 [recombinant, as04 adjuvanted] suspension for injection vial

glaxosmithkline australia pty ltd - hpv type 18 l1 protein, quantity: 20 microgram; hpv type 16 l1 protein, quantity: 20 microgram - injection, suspension - excipient ingredients: water for injections; sodium chloride; 3-o-desacyl-4'-monophosphoryl lipid a; monobasic sodium phosphate; aluminium hydroxide hydrate - cervarix is indicated in females from 10 to 45 years of age for the prevention of persistent infection, premalignant cervical lesions and cervical cancer caused by human papillomavirus types 16 and 18. immunogenicity studies have been conducted in females aged 10 to 14 years and 26 to 45 years to link efficacy in females aged 15 to 25 years to other populations. (see precautions and clinical trials). cervarix is indicated in females from 10 to 45 years for the prevention of cervical cancer by protecting against incident and persistent infections, cytological abnormalities including atypical squamous cells of undetermined significance (asc-us) and cervical intraepithelial neoplasia (cin), cin 1 and pre-cancerous lesions (cin 2 and cin 3) caused by human papillomavirus types 16 and 18. immunogenicity studies have been conducted in females aged 10 to 14 years and 26 to 45 years to link efficacy in females aged 15 to 25 years to other populations.

GARDASIL HPV 6 L1 Protein / HPV 11 L1 Protein / HPV 16 L1 Protein / HPV 18 L1 Protein 20,40,40,20 micrograms/0.5mL sterile liqui Australia - English - Department of Health (Therapeutic Goods Administration)

gardasil hpv 6 l1 protein / hpv 11 l1 protein / hpv 16 l1 protein / hpv 18 l1 protein 20,40,40,20 micrograms/0.5ml sterile liqui

merck sharp & dohme (australia) pty ltd - hpv type 6 l1 protein, quantity: 20 microgram; hpv type 11 l1 protein, quantity: 40 microgram; hpv type 16 l1 protein, quantity: 40 microgram; hpv type 18 l1 protein, quantity: 20 microgram - injection, suspension - excipient ingredients: aluminium; histidine; polysorbate 80; borax; water for injections; sodium chloride - gardasil is indicated in females aged 9 through 45 years* for the prevention of cervical, vulvar, vaginal and anal cancer, precancerous or dysplastic lesions, genital warts, and infection caused by human papillomavirus (hpv) types 6, 11, 16, and 18 (which are included in the vaccine). gardasil is indicated in males 9 through 26 years of age for the prevention of anal cancer, precancerous or dysplastic lesions, external genital lesions and infection caused by hpv types 6, 11, 16, and 18 (which are included in the vaccine). *immunogenicity studies have been conducted to link efficacy in females and males aged 16 to 26 years to the younger populations.

L.C.E. SANDOZ 75/18.75/200 levodopa 75 mg, carbidopa  (as carbidopa monohydrate) 18.75 mg and entacapone 200 mg film-coated tablet bottle Australia - English - Department of Health (Therapeutic Goods Administration)

l.c.e. sandoz 75/18.75/200 levodopa 75 mg, carbidopa (as carbidopa monohydrate) 18.75 mg and entacapone 200 mg film-coated tablet bottle

sandoz pty ltd - carbidopa monohydrate, quantity: 20.25 mg (equivalent: carbidopa, qty 18.75 mg); entacapone, quantity: 200 mg; levodopa, quantity: 75 mg - tablet, film coated - excipient ingredients: polysorbate 80; maize starch; hypromellose; croscarmellose sodium; iron oxide red; titanium dioxide; povidone; magnesium stearate; glycerol; mannitol; sucrose - l.c.e. sandoz 75/18.75/200 is indicated for the management of patients with parkinson's disease who are experiencing motor fluctuations.

Dugmectin 18.7 mg/g Oral Paste for Horses Ireland - English - HPRA (Health Products Regulatory Authority)

dugmectin 18.7 mg/g oral paste for horses

eco animal health europe limited - ivermectin - oral paste - 18.7 milligram(s)/gram - ivermectin

TRAMADOL HYDROCHLORIDE tablet, extended release United States - English - NLM (National Library of Medicine)

tramadol hydrochloride tablet, extended release

sun pharmaceutical industries, inc. - tramadol hydrochloride (unii: 9n7r477wck) (tramadol - unii:39j1lgj30j) - tramadol hydrochloride extended-release tablets are indicated for the management of severe and persistent pain  that requires an extended treatment period with a daily opioid analgesic and for which alternative treatment options are inadequate. limitations of use - because of the risks of addiction, abuse, and misuse, with opioids, which can occur at any dosages or duration, and because of the greater risks of overdose and death with extended-release/long-acting opioid formulations [see warnings] , reserve tramadol hydrochloride extended-release tablets for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. - tramadol hydrochloride extended-release tablets are not indicated as an as-needed (prn) analgesic. tramadol hydrochloride extended-release tablets are contraindicated for: - all children younger than 12 years of age [see warnings ]. - postoperative management in children younger than 18 years of age following tonsillectomy and/or adenoidectomy [see warnings ]. tramadol hydrochloride extended-release tablets are also contraindicated in patients with: - significant respiratory depression [see warnings ] - acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment [see warnings ] - known or suspected gastrointestinal obstruction, including paralytic ileus [see warnings ] - hypersensitivity to tramadol (e.g., anaphylaxis) [see adverse reactions ] - concurrent use of monoamine oxidase inhibitors (maois) or use within the last 14 days [see precautions; drug interactions ]

Ecomectin 18,7 mg/g or. paste pre-filled syr. Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

ecomectin 18,7 mg/g or. paste pre-filled syr.

eco animal health europe ltd. - ivermectin 18,7 mg/g - oral paste - 18,7 mg/g - ivermectin 18.7 mg/g - ivermectin - horse

Equest Gel Oral 18,92 mg/g or. gel pre-filled syr. Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

equest gel oral 18,92 mg/g or. gel pre-filled syr.

zoetis belgium sa-nv - moxidectine 18,92 mg/g - oral gel - 18,92 mg/g - moxidectin 18.92 mg/g - moxidectin - horse

Eqvalan 18.7 mg/g or. paste pre-filled syr. Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eqvalan 18.7 mg/g or. paste pre-filled syr.

boehringer ingelheim animal health belgium sa-nv - ivermectin 18,7 mg/g - oral paste - 18,7 mg/g - ivermectin 18.7 mg/ml - ivermectin - horse

Furexel Ivermectine 18.7 mg/g or. paste pre-filled syr. Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

furexel ivermectine 18.7 mg/g or. paste pre-filled syr.

boehringer ingelheim animal health belgium sa-nv - ivermectin 18,7 mg/g - oral paste - 18,7 mg/g - ivermectin 18.7 mg/g - ivermectin - horse

Ivermax 18,7 mg/g or. paste pre-filled syr. Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

ivermax 18,7 mg/g or. paste pre-filled syr.

eco animal health europe ltd. - ivermectin 18,7 mg/g - oral paste - 18,7 mg/g - ivermectin 18.7 mg/g - ivermectin - horse